43 Posts Not To Miss From ESMO24 Day 2
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the Fira Barcelona Gran Via.
This significant event, organized by the European Society for Medical Oncology (ESMO), attracted over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives from around the globe.
The congress featured nearly 300 sessions, presenting over 2,000 abstracts, with a focus on the latest advancements in cancer research and treatment. Key topics included new therapeutic combinations for various cancers, the long-term effects of immunotherapy, and innovative approaches integrating artificial intelligence into cancer care.
Here are some highlights from ESMO Congress 2024 Day 2:
“The ESMO Women for Oncology Committee has been actively monitoring the representation of Female Oncologists in leadership roles since 2015. Despite progress in some areas, the representation of women in oncology leadership remains low, particularly at congresses, on society boards, and as leading authors in publications.
Helena Linardou will dive deeper in findings from this work on Monday, 16 September at 14:45 during the Policy and preventive strategies Mini Oral session. We encourage all delegates to attend for additional insights.”
“ESMO24 Lung Orals.
Super presentation by Benjamin Besse on mechanisms of acquired resistance to ami/laz in EGFR+ NSCLC shows potentially less RB1 loss/sclc transformation A clinically relevant outcome if confirmed clinically, one to watch.”
“Treatment landscape for EGFR lung cancer is getting more complex – for clinicians and patients. But as Dr Jurgen Wolf says at ESMO24 ‘Always good to have several arrows in your quiver.’
Absolutely agree. Stratifying which patients are best for which option is key.”
“Gene signatures have revolutionized treatment for HR+ eBC. Could they also refine treatment for more aggressive subtypes? Intriguing data of TNBC-DX from a pooled analysis of 418 patients treated with neoadjuvant taxane-based chemo.”
“To the moon! Huge congratulations to Toni Choueiri for the The Lancet and NEJM paper!
Now that we have landed in the moon – off to Mars! Exhilarating discussions about one of the greatest oncology meetings ever with Toni Choueiri, Sumanta Pal
Stay tuned.”
“Thanks to the entire team of our French thoracic oncology group IFCT (and investigators) for successfully conducting this clinical trial in BRAFV600E mutated NSCLC patients, presented this morning in an oral session at ESMO! A new therapeutic option for our patients…”
“Young talent Manon de Graaf from The Netherlands Cancer Institute, Marleen Kok Lab presenting data on patients with stage 1 TNBC. Good registries thanks to IKNL allow for analysis of populations excluded from most trials!”
“SCRI Oncology Partners President Dr. David Spigel presents Belrestotug and Dostarlimab (‘my god!’ says Dr Ben Besse).”
“ESMO24 Lung Orals.
Provocative questions:
- Corey Langer ‘is RB1 loss on cfDNA indicative of clinical sclc transformation?’
- Tony Mok ‘does LaG3+ correlate with response to nivo-rel’
- David Gandara ‘methylation may matter in EGFR+ acq resistance’”
“Long awaited results of the first phase II randomized trial evaluating a ct-DNA guided rechallenge strategy with Cet+Iri (CITRIC)
ORR 0% vs 9.7%
DCR 44.4% vs 74.2%
Another piece of the puzzle waiting for the ongoing PARERE trial by GONO Foundation.”
“Hanging out with some of my favorite drug development colleagues at the speaker center Udai Banerji, Chris Le Tourneau, and the amazing one and only fearless sarcoma extraordinaire Robin Lewis Jones!!!”
“New data for intermediate HCC at ESMO24 from LEAP-012 trial
PFS/ORR benefit for LenvaPembro+TACE (vs TACE)
OS promising
Toxicity acceptable
Systemic+TACE as SOC may be close to be a reality!! (2nd +ve study EMERALD-1)”
“ESMO24 insightful session on the future of Metastatic Prostate Cancer.
Neeraj Agarwal discussing T-cell engagers and innovative therapies on the horizon!”
“Meeting with the best of the best oncology colleagues in the universe.
Thank you to ESMO for bringing us all together. It takes a global village.”
“Dr. Benjamin Besse presents data from ARROS-1 study of NVL-520 (zidesamtinib) in ROS1 NSCLC. RP2D established at 100mg daily. Rationally designed drug with high CNS efficacy and avoiding TRK will help reduce toxicity.”
“Double Antibody Drug conjugate (DAD): Ph I trial of sacituzumab govitecan + enfortumab vedotin in ≥2L tx of heavily pre-treated mUC (n=23)
ORR: 70% (CR: 17%; PR: 53%)
DoR: 10 mo.”
“ong term survival with neoadjuvant ICI in melanoma, pooled data from INMC presented by Georgina Long. Combo IO with highest rates of MPR and 78% EFS at 3 years. 3y RFS EXCELLENT 94% for those who have MPR. MPR strongly predicts 3y OS.”
“Fantastic ESMO24.
Wonderful group with diversity, talent, passion and love for oncology! Looking forward to next days!”
“Let the science flow at the poster session.”
“Outstanding talk from Silke Gillessen elegantly presenting PEACE-3 phase 3 trials first results. Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement + significant OS benefit.”
“What a great network party.
Thanks for having us ESMO pecially.”
“Huge congrats to Pedro Barata who drove this important analysis of SWOG 1500, published just ahead of ESMO24 in Journal of Clinical Oncology.
Lots of dialogue here in Barcelona around management of non clear kidney cancer; I think this paper and data from SUNNIFORECAST are impt parts of the dialogue.”
“Presidential Session ESMO24.
PEACE-3: Enza+ Ra223 vs Senza
Speaker: Silke Gillessen
- mPFS 19.4 vs 16.4m HR 0.69
- TTT HR 0.57
G3 28% combo vs 19% Enza alone Discussed by Dr. Fizazi.”
“Honored to have chaired a symposium on bladder and prostate cancer at ESMO24. Huge thanks to my wonderful co-chair Alison Birtle, all the speakers, Elena Verzoni and the numerous participants. It was both informative and fun!”
“ESMO2024: IA of GALAXIES Lung-201: Ph2, Belrestotug (anti-TIGIT) + Dostarlimab in Previously Untreated PD-L1 High (TPS >/=50%) NSCLC. Meaningfull improvement ORR 35.7% vs. 67-76%. Higher grade 3> AEs in the combo cohort. GALAXIES Lung-301 trial phase 3 ongoing.”
“Exarafenib, panRAFinh+Binimetinib
ORR 33% NRAS mut, DCR
Dr. Cassier: Tovorafenib, BRAF/CRAFfus/amplif
Dr. Vieito
ORR 50% melanoma+CNS, DCR 75%
Discussed by Teresa Amaral ‘Golden circle’.”
“New SOC for high-risk locally advanced cervical cancer (LACC)?
The phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study shows that the addition of pembro to CCRT leads to a significant and clinically meaningful improvement in OS with a manageable safety profile!”
“Presidential for Silke Gillessen.
Radium223 + enza vs enza alone shows a PFS and OS advantage in metastatic CRPC. PEACE3 is an investigator trial and rejuvenates radium-223 in prostate cancer. 0.69 HR for PFS and OS!!!”
“Amazing and clear overview of T cell engagers in Pca and future therapeutic strategies by the one and only Neeraj Agarwal.
Finally a lot of excitement with IO in Pca!”
“Very prepared Turkish, Swiss and Dutch – they all came with super fans! But could not see Yuksel Urun, Solange Peters or Myriam Chalabi!!
The Argentina team really looks good!”
“Dr. Cristiane Bergerot’s presentation at ESMO24 was informative!
In this session led by Matteo Lambertini, Dr. Cris explored patient-reported outcomes and strategies to improve how sexual health is measured and addressed in oncology, focusing on both patient and provider perspectives.”
“Crystal clear talk from Misha Beltran highlighting role of DLL3 in neuroendocrine prostate cancer. Although some of the early data with tarlatamab may not be very supportive, eager to see MK6070 – interesting signal in NEPC.”
“Presidential ESMO24 -Practice changing trials
LEAP-012
Adding lenvatinib + pembro to TACE in intermediate-stage HCC
mPFS: 14.6 vs 10 mo; HR: 0.66, 95% CI: 0.51-0.84; P = 0.0002
OS immature
Grade 3-5 TRAEs: 71.3% vs 31.5%.”
“At last – a new treatment for patients with advanced anal SCC.
Pod1um-303 shows 6m mOS for anti-PD-1 + chemo
ESMO24 Presidential.”
“Zipalertinib in EGFR Ex20Ins, inc. post Ami +/- other Ex20 agent
ORR 50%, DCR 87% post ami pop
mPFS 9.7m
Low TRAE, inc liw Gr3 tox / rash
Need CNS data
Better tolerated than 1G TKIs
Huge need for post-Ami target therapy
Need access to trials.”
“Looking forward to my amazing friend Petros Grivas discussing the Presidential Session. Stay tuned for his insightful analysis as the discussant on the NIAGARA trial LBA5 – A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA) Tom Powles
Lecture Time: 17:14 – 17:26
Barcelona Auditorium – Hall 2
Dr. Grivas has assigned seating.”
“Next up we have sarcoma immunotherapy rockstar Breelyn Wilky taking us on a tour of landmark immunotherapy trials in sarcomas. Checkpoint inhibitors are only the beginning, the answer is in checkpoint Plus and cellular-therapies.
“Efficacy and safety of ivonescimab +/-ligufalimab with FOLFOXIRI in 1L mCRC
Phs II
ivonescimab: PD-1/VEGF bispecific
ligufalimab: CD47
ORR 81 vs 88%
9-mo PFS rate 81 vs 86 mo
AE ≥3 68% vs. 66%
Interesting, but most likely not for all comers.”
“Over 40,000 members are part of the ESMO family. Thank you to all for believing in this society. Special thanks go to the presidents, the executive and council members and the membership committee.”
“POD1UM-303/InterAACT 2
Inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal
Randomized: Carbo/Taxol vs. Carbo/Taxol + retifanlimab
Addition of retifanlimab associated with:
OS 29 vs 23 m
PFS 9 vs 7 m
New SOC!!”
“At ESMO24 Fedro Peccatori presenting first evidences about safety of breastfeeding in pts in POSITIVE trial Breastfeeding did not increase BC events with 2y cumulative incidence of 3.6% in breastfeeding vs 3.1% in non-breastfeeding group (HR: 1.12, CI 0.28 – 4.5).”
“PEACE-3 at ESMO24 Practice changing for 1L mCRPC patients who didn’t use ARPI in mCSPC
1L mCRPC patients with bone metastases
1:1 to ENZ vs ENZ-RAD (6 cycles)
Primary endpoint: rPFS
446 men, FU 42.2 months
HR for rPFS 0.69 (p=0.0009)
HR for OS 0.69 (p=0.0031)
Bone-protecting agent is mandatory!!!
More adverse grade 3 or greater AE (19 vs 28%).”
“Excellent discussion of pitfalls and practical implications of the PEACE 3 data by Prof Karim Fizazi.
1. Clinical benefit clear PFS/OS
2. Fracture prevention
3. BP monitoring
4. Only for ARPI naive patients
5. More data to come!”
More posts featuring ESMO24 on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023